State-of-the-art management of complications of myeloma and its treatment

Advances in Hematology

Volumn 2010, Issue , 2010, Pages

  Baz, Rachid ^a   Hartley Brown, Monique A ^a   Sullivan, Daniel M ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; ANTHRACYCLINE; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CORTICOSTEROID; COTRIMOXAZOLE; DENOSUMAB; DEXAMETHASONE; ENOXAPARIN; HEPARIN; IMMUNOGLOBULIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; PAMIDRONIC ACID; PLACEBO; PNEUMOCOCCUS VACCINE; QUINOLONE DERIVATIVE; THALIDOMIDE; VALACICLOVIR; VINCRISTINE; WARFARIN; ZOLEDRONIC ACID;

BACTERIAL INFECTION; BONE ATROPHY; BONE DISEASE; CAST NEPHROPATHY; CLINICAL TRIAL; COMPRESSION FRACTURE; DIAGNOSTIC IMAGING; DRUG MEGADOSE; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HERPES ZOSTER; HUMAN; IMMUNOGLOBULIN DEFICIENCY; INFECTIOUS COMPLICATION; JAW OSTEONECROSIS; KIDNEY AMYLOIDOSIS; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LOW DRUG DOSE; MORTALITY; MULTIPLE MYELOMA; NEPHROTOXICITY; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT INFECTION; REVIEW; SURVIVAL RATE; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

EID: 77955358746     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2010/343089     Document Type: Review

References (72)

1. Rajkumar S. V., Hayman S., Gertz M. A., Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma Journal of Clinical Oncology 2002 20 21 4319 4323
2. Rajkumar S. V., Hayman S. R., Lacy M. Q., Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma Blood 2005 106 13 4050 4053
3. APEX (Assessment of Proteasome inhibition for Extending remissions) trial: phase III randomized, multicenter, placebo-controlled trial to evaluate the efficacy and safety of bortezomib versus dexamethasone in patients with recurrent or treatment-resistant multiple myeloma Clinical Advances in Hematology Oncology 2003 1 190
4. Attal M., Harousseau J. L., Facon T., Single versus double autologous stem-cell transplantation for multiple myeloma The New England Journal of Medicine 2003 349 26 2495 2502
5. Jawed I., Lee C. M., Tward J. D., Survival outcomes for multiple myeloma over three decades: a surveillance, epidemiology, and end results (SEER) analysis Journal of Clinical Oncology 2007 25 18s. abstract no. 8019
6. Durie B. G. M., Salmon S. E., A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival Cancer 1975 36 3 842 854
7. Clark A. D., Shetty A., Soutar R., Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma Blood Reviews 1999 13 2 79 90
8. Chim C. S., Li F. K., Chan K. W., Cast nephropathy in multiple myeloma Haematologica 2004 89 4, article e60
9. Basi-Juki N., Kes P., Labar B., Myeloma kidney: pathogenesis and treatment Acta medica Croatica 2001 55 4-5 169 175
10. Arimura A., Li M. I. N., Batuman V., Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury Blood 2006 107 2 661 668
11. Sanders P. W., A new twist in myeloma treatment Blood 2006 107 2 413 414
12. Kanno Y., Okada H., Nemoto H., Sugahara S., Nakamoto H., Suzuki H., Crystal nephropathy: a variant form of myeloma kidneya case report and review of the literature Clinical Nephrology 2001 56 5 398 401
13. Leung N., Gertz M. A., Zeldenrust S. R., Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains Kidney International 2008 73 11 1282 1288
14. Johnson W. J., Kyle R. A., Pineda A. A., O'Brien P. C., Holley K. E., Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy Archives of Internal Medicine 1990 150 4 863 869
15. Clark W. F., Garg A. X., Blake P. G., Rock G. A., Heidenheim A. P., Sackett D. L., Effect of awareness of a randomized controlled trial on use of experimental therapy Journal of the American Medical Association 2003 290 10 1351 1355
16. Hutchison C. A., Cook M., Heyne N., European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial Trials 2008 9 55
17. Mller A. M. S., Geibel A., Neumann H. P. H., Primary (AL) amyloidosis in plasma cell disorders Oncologist 2006 11 7 824 830
18. Bahlis N. J., Lazarus H. M., Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted? Bone Marrow Transplantation 2006 38 1 7 15
19. Bird J. M., Fuge R., Sirohi B., The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study British Journal of Haematology 2006 134 4 385 390
20. Glenner G. G., Amyloid deposits and amyloidosis. The -fibrilloses. (first of two parts) The New England Journal of Medicine 1980 302 23 1283 1292
21. Gertz M. A., Lacy M. Q., Dispenzieri A., Hayman S. R., Kumar S., Transplantation for amyloidosis Current Opinion in Oncology 2007 19 2 136 141
22. Randall R. E., Williamson W. C. Jr., Mullinax F., Tung M. Y., Still W. J., Manifestations of systemic light chain deposition American Journal of Medicine 1976 60 2 293 299
23. Ivanyi B., Renal complications in multiple myeloma Acta Morphologica Hungarica 1989 37 3-4 235 243
24. Hill P. G., Forsyth J. M., Rai B., Mayne S., Serum free light chains: an alternative to the urine bence jones proteins screening test for monoclonal gammopathies Clinical Chemistry 2006 52 9 1743 1748
25. Pozzi C., D'Amico M., Fogazzi G. B., Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors American Journal of Kidney Diseases 2003 42 6 1154 1163
26. Leung N., Lager D. J., Gertz M. A., Wilson K., Kanakiriya S., Fervenza F. C., Long-term outcome of renal transplantation in light-chain deposition disease American Journal of Kidney Diseases 2004 43 1 147 153
27. Oken M. M., Pomeroy C., Weisdorf D., Bennett J. M., Prophylactic antibiotics for the prevention of early infection in multiple myeloma American Journal of Medicine 1996 100 6 624 628
28. Rajkumar S. V., Jacobus S., Callander N., Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group Journal of Clinical Oncology 2007 25 18s. abstract no. LBA8025
29. San Miguel J. F., Schlag R., Khuageva N. K., Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma The New England Journal of Medicine 2008 359 9 906 917
30. Chapel H. M., Lee M., Hargreaves R., Pamphilon D. H., Prentice A. G., Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma The Lancet 1994 343 8905 1059 1063
31. Robertson J. D., Nagesh K., Jowitt S. N., Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma British Journal of Cancer 2000 82 7 1261 1265
32. Borello I., The immunomodulatory role of lenalidomide on Prevnar responses in patients with relapsed multiple myeloma: a comprehensive analysis of the immune response Blood 2008 112 2772
33. Carroll I., Gaeta R., Mackey S., A vaccine to prevent herpes zoster The New England Journal of Medicine 2005 353 13 1414 1415
34. Kessler K. M., A vaccine to prevent herpes zoster The New England Journal of Medicine 2005 353 13 1414 1415. author reply
35. Vega M., Inhibition of NF-Kb cell signaling and induction of the metastasis suppressor and immune surveillance cancer gene RKIP expression in B-NHL by the novel humanized BM-Ca anti-CD20 monoclonal antibody: implication in chemo and immune-sensitization Blood 2008 112 2613
36. Kyle R. A., Multiple myeloma. Review of 869 cases Mayo Clinic Proceedings 1975 50 1 29 40
37. D'Sa S., Abildgaard N., Tighe J., Shaw P., Hall-Craggs M., Guidelines for the use of imaging in the management of myeloma British Journal of Haematology 2007 137 1 49 63
38. Mahfouz T., Miceli M. H., Saghafifar F., 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes Journal of Clinical Oncology 2005 23 31 7857 7863
39. Woolfenden J. M., Pitt M. J., Durie B. G. M., Moon T. E., Comparison of bone scintigraphy and radiography in multiple myeloma Radiology 1980 134 3 723 728
40. Hughes D. E., Wright K. R., Uy H. L., Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo Journal of Bone and Mineral Research 1995 10 10 1478 1487
41. Berenson J. R., Lichtenstein A., Porter L., Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma The New England Journal of Medicine 1996 334 8 488 493 (Pubitemid 26067736)
42. Major P., Lortholary A., Hon J., Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials Journal of Clinical Oncology 2001 19 2 558 567
43. Migliorati C. A., Casiglia J., Epstein J., Jacobsem P. L., Siegel M. A., Woo S.-B., Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper Journal of the American Dental Association 2005 136 12 1658 1668
44. Ruggiero S. L., Mehrotra B., Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management Annual Review of Medicine 2009 60 85 96
45. Berenson J. R., Hillner B. E., Kyle R. A., American society of clinical oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma Journal of Clinical Oncology 2002 20 17 3719 3736
46. Reddy G. K., Mughal T. I., Roodman G. D., Novel approaches in the management of myeloma-related skeletal complications Supportive Cancer Therapy 2006 4 1 15 18
47. Roodman G. D., Novel targets for myeloma bone disease Expert Opinion on Therapeutic Targets 2008 12 11 1377 1387
48. Roodman G. D., Bone building with bortezomib Journal of Clinical Investigation 2008 118 2 462 464
49. Coleman E. A. N. N., Coon S., Hall-Barrow J., Richards K., Gaylor D., Stewart B., Re: Coleman et al. Feasibility of exercise during treatment for multiple myeloma. Cancer Nursing. 2003;26(5):410419 Cancer Nursing 2008 31 4 263 264
50. Ezzo J., Berman B., Hadhazy V. A., Jadad A. R., Lao L., Singh B. B., Is acupuncture effective for the treatment of chronic pain? A systematic review Pain 2000 86 3 217 225
51. Cotten A., Boutry N., Cortet B., Percutaneous vertebroplasty: state of the art Radiographics 1998 18 2 311 320
52. Cotten A., Dewatre F., Cortet B., Percutaneous vertebroplasty for osteolytic metastases and myeloma: effects of the percentage of lesion filling and the leakage of methyl methacrylate at clinical follow-up Radiology 1996 200 2 525 530
53. Lieberman I. H., Dudeney S., Reinhardt M. K., Bell G., Initial outcome and efficacy of kyphoplasty in the treatment of painful osteoporotic vertebral compression fractures Spine 2001 26 14 1631 1637
54. Lieberman I., Reinhardt M. K., Vertebroplasty and kyphoplasty for osteolytic vertebral collapse Clinical Orthopaedics and Related Research 2003 415 S176 S186
55. Karwicki L., Kmieciak M., Kopka M., Surgical treatment of metastasic tumors to long bones in the material of the unit Ortopedia Traumatologia Rehabilitacja 2003 5 3 358 363
56. Srkalovic G., Cameron M. G., Rybicki L., Deitcher S. R., Kattke-Marchant K., Hussein M. A., Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease Cancer 2004 101 3 558 566
57. Baz R., Li L., Kottke-Marchant K., The role of aspirin in the prevention of thrombotic complication of thalidomide and anthracycline-based chemotherapy for multiple myloma Mayo Clinic Proceedings 2005 80 12 1568 1574
58. Zangari M., Elice F., Fink L., Tricot G., Thrombosis in multiple myeloma Expert Review of Anticancer Therapy 2007 7 3 307 315
59. Rajkumar S. V., Blood E., Vesole D., Fonseca R., Greipp P. R., Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group Journal of Clinical Oncology 2006 24 3 431 436
60. Zangari M., Saghafifar F., Anaissie E., Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications Blood Coagulation and Fibrinolysis 2002 13 3 187 192
61. Palumbo A., Rajkumar S. V., Dimopoulos M. A., Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma Leukemia 2008 22 2 414 423
62. Palumbo A., Facon T., Sonneveld P., Thalidomide for treatment of multiple myeloma: 10 years later Blood 2008 111 8 3968 3977
63. Baz R., Alemany C., Green R., Hussein M. A., Prevalence of vitamin B12 deficiency in patients with plasma cell dyscrasias: a retrospective review Cancer 2004 101 4 790 795
64. Dispenzieri A., Kyle R. A., Neurological aspects of multiple myeloma and related disorders Best Practice and Research: Clinical Haematology 2005 18 4 673 688
65. Argyriou A. A., Iconomou G., Kalofonos H. P., Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature Blood 2008 112 5 1593 1599
66. Richardson P. G., Sonneveld P., Schuster M. W., Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline British Journal of Haematology 2009 144 6 895 903
67. Mileshkin L., Stark R., Day B., Seymour J. F., Zeldis J. B., Prince H. M., Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring Journal of Clinical Oncology 2006 24 27 4507 4514
68. Dimopoulos M. A., Kastritis E., Rajkumar S. V., Treatment of plasma cell dyscrasias with lenalidomide Leukemia 2008 22 7 1343 1353
69. Arastu-Kapur S., Shenk K., Parlati F., Bennett M. K., Non-proteasomal targets of proteasome inhibitors bortezomib and carfilzomib Proceedings of the 5th ASH Annual Meeting and Exposition 2008. abstract 2657
70. Vlasveld L. T., Low cobalamin (vitamin BI2) levels in multiple myeloma: a retrospective study Netherlands Journal of Medicine 2003 61 8 249 252
71. Rosenstock J., Tuchman M., Lamoreaux L., Sharma U., Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial Pain 2004 110 3 628 638
72. Ziegler D., Hanefeld M., Ruhnau K. J., Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant -lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study) Diabetologia 1995 38 12 1425 1433